ovalbumin and Cardiovascular-Diseases

Several of the most prevalent etiological factors which contribute towards global death rates are associated with cardiovascular diseases (CVDs), which include a range of conditions such as angina, rheumatic heart disease, and venous thrombosis. Extensive research has been conducted into the role played by oxidative stress and inflammation in the functional transformations associated with the progression of CVDs, while the research findings from these investigations have been both fruitful and informative. In view of the adverse secondary effects that result from the clinical administration of many synthetic medications, research which explored the treatment of severe and long-lasting conditions, including CVDs, has primarily centered on the potential benefits displayed by natural agents, one of which is food protein-based bioactive peptides. Most importantly, previous research has revealed the possible benefits associated with these products' anti-inflammatory and antioxidant characteristics. In light of these considerations, this paper aims to review the degree to which ovotransferrin (otrf, also referred to as conalbumin) and otrf-derived peptides, including IRW, IQW, and KVREGT, are, by virtue of their anti-inflammatory and antioxidant characteristics, viable treatment agents for endothelial dysfunction and the prevention of CVD.

Topics: Anti-Inflammatory Agents; Antioxidants; Cardiovascular Diseases; Conalbumin; Endothelial Cells; Humans; Ovalbumin; Peptides

While animal and in vitro data demonstrate vasodilatory effects of egg white-derived peptides, human studies are lacking. We investigated for the first time the effects of an egg ovalbumin-derived protein hydrolysate on blood pressure (BP) and cardiovascular risk.. A double-blind, placebo-controlled randomized crossover trial was implemented in 75 adults aged 50-70 years with systolic BP (130-≤ 150 mmHg). Participants were randomized to an egg ovalbumin-derived protein hydrolysate (3 g/day) or placebo (3 g/day). Participants completed two 6-week periods separated by a 3-week washout.. Data from 65 participants with a mean systolic BP (135.1 ± 11 mmHg) were included. Mean office and central BP and arterial stiffness (assessed by carotid-femoral pulse wave velocity (cfPWV) or pulse wave analysis (PWA)) did not change over time and no significant differences were observed between the egg protein hydrolysate and placebo groups (P > 0.05). Similarly, no significant effects of this egg ovalbumin-derived protein hydrolysate on blood lipid and glucose concentrations (P > 0.05) were observed.. This is the first dietary intervention to investigate the effects of egg ovalbumin-derived protein hydrolysates on cardiovascular risk in humans. Despite promising findings from animal and in vitro studies, this RCT does not support the hypothesis that consumption of an egg ovalbumin-derived protein hydrolysate for 6 weeks in adults with a high-normal BP results in a reduction in BP or the modification of cardiovascular risk.

Topics: Aged; Blood Pressure; Cardiovascular Diseases; Comorbidity; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypertension; Ireland; Male; Middle Aged; Ovalbumin; Protein Hydrolysates; Pulse Wave Analysis; Risk Factors

Cardiovascular disease remains the leading cause of death globally, and heart failure (HF) represents its terminal stage. Asthma, one of the most common chronic diseases, has been reported to be associated with an increased risk of cardiovascular disease. However, the link between asthma and HF has rarely been studied, and the possible mechanisms by which asthma affects HF are unclear. This study aimed to explore the influence of asthma on HF and the possible mechanisms. We analyzed data from the National Health and Nutrition Examination Survey and found a higher prevalence of HF among asthmatic individuals, and identified an independent association between HF and asthma. Subsequently, we produced mice with concurrent ovalbumin (OVA) sensitization-induced allergic asthma and angiotensin Ⅱ infusion-induced cardiac remodeling to explore the effect of asthma on cardiac remodeling in vivo. The results showed that OVA-induced asthma impaired heart function and aggravated cardiac remodeling in mice. We also found that OVA sensitization increased the expression levels of immunoglobulin E (IgE) in serum and IgE receptor (FcεR1) in the heart, and enhanced the activation of downstream signaling molecules of IgE-FcεR1 in the heart. Importantly, blockage of IgE-FcεR1 using FcεR1-deficient mice or an anti-IgE antibody prevented asthma-induced decline of cardiac function, and alleviated cardiac remodeling. These findings demonstrate the adverse effects of allergic asthma on the heart, and suggest the potential application of anti-IgE therapy in the treatment of asthma complicated with heart conditions.

Topics: Angiotensin II; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cardiovascular Diseases; Disease Models, Animal; Heart Failure; Immunoglobulin E; Mice; Mice, Inbred BALB C; Nutrition Surveys; Ovalbumin; Ventricular Remodeling

This study was designed to determine the effects of different calcium concentrations on the perfused isolated guinea-pig heart preparation subjected to cardiac anaphylaxis. Following challenge both physiological and biochemical effects were determined on hearts from guinea-pigs previously sensitized to ovalbumin. Perfusion media containing either 1,2.54 or 5 mM of calcium was used. In comparison to nonsensitized controls challenged to ovalbumin, challenged sensitized hearts (CSH) perfused with 1 mM Ca2+ showed an initial increase in dF/dt, a prolonged rise in H.R. and depressed coronary flow. Raising the calcium concentration to either 2.54 or 5 mM in CSH preparations resulted in a marked increase in the release of lactate dehydrogenase (LDH) into the coronary effluent and depressed coronary flow. Perfusing CSH preparations with increasingly higher calcium concentrations more often produced severe tachyarrhythmias and fibrillation. The highest level of histamine released into the coronary effluent occurred immediately following challenge and then declined exponentially over the next 20 min. Both challenge and the administration of histamine induced an immediate but transient increase in H.R., a rise in dF/dt, and LDH release. The infusion of histamine produced an increase in coronary flow, but on porcine tubular coronary arterial segments only a direct constricting effect was obtained. The prior administration of cimetidine (10(-5) M) attenuated the rise in LDH and dF/dt in CSH and nonsensitized preparations infused with histamine (3 micrograms). However, although cimetidine did not affect the decreased coronary flow in CSH preparations, it initially attenuated the rise in coronary flow in preparations infused with histamine. These results suggest that calcium enhances the likelihood of tachyarrhythmias in cardiac anaphylaxis. The release of LDH in histamine-infused preparations and those CSH preparations perfused with 2.54 and 5 mM calcium-containing media also suggests the possibility that calcium enhances the damaging effects on the myocardial cell in cardiac anaphylaxis.

Topics: Anaphylaxis; Animals; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Cimetidine; Coronary Circulation; Female; Guinea Pigs; Heart; Heart Rate; Histamine; In Vitro Techniques; Kinetics; L-Lactate Dehydrogenase; Male; Myocardial Contraction; Ovalbumin; Perfusion

Brown-Norway rats, sensitized with trinitrophenyl (TNP) haptenized ovalbumin and AIPO4 as adjuvant 12 days before, were challenged with trinitrophenyl haptenized bovine serum albumin intravenously, while lung function (Vt, V, Ppl, Fres, Cdyn, and Rl) and cardiovascular function (BP and Fheart) were measured continuously. This resulted in a highly reproducible, plasma IgE-antiTNP related, immediate anaphylactic response characterized by a short-lasting (8-10 min) bronchoconstriction, together with a long-lasting fall in blood pressure. All rats died in shock within 21-150 min. This method is simple and appeared to be highly reproducible and therefore suitable to screen or study antiallergic drugs in vivo.

Topics: Anaphylaxis; Animals; Bronchial Diseases; Cardiovascular Diseases; Disease Models, Animal; Female; Haptens; Immunoglobulin E; Male; Ovalbumin; Rats; Rats, Inbred BN; Serum Albumin, Bovine; Trinitrobenzenes

Topics: Anaphylaxis; Animals; Antigens; Cardiovascular Diseases; Chickens; Diethylcarbamazine; Freund's Adjuvant; Muscle, Smooth; Ovalbumin; Rats; SRS-A

Topics: Anaphylaxis; Animals; Cardiovascular Diseases; Desensitization, Immunologic; Dextrans; Emphysema; Guinea Pigs; Histamine H1 Antagonists; Immune Sera; Ovalbumin; Tachyphylaxis

Topics: Anaphylaxis; Animals; Antigen-Antibody Reactions; Aorta; Blood Pressure; Calcium Chloride; Cardiac Output; Cardiovascular Diseases; Female; Guinea Pigs; Heart; Heart Rate; Heart-Lung Machine; Hexobarbital; Histamine; Histamine H1 Antagonists; Male; Norepinephrine; Ovalbumin; Pyridines; Quinidine; Reserpine; Tyramine

Topics: Adolescent; Adult; Albumins; Animals; Antibodies; Antigen-Antibody Reactions; Cardiovascular Diseases; Cattle; Child; Collagen Diseases; Communicable Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Female; gamma-Globulins; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypersensitivity; Infant; Infant, Newborn; Insulin; Iodine Isotopes; Lactalbumin; Maternal-Fetal Exchange; Milk; Nervous System Diseases; Ovalbumin; Pregnancy; Respiratory Tract Diseases; Serum Albumin; Serum Albumin, Bovine; Skin Tests; Viral Vaccines